PIK3C2G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL48581	0.53	4/20
SCHEMBL50025	0.53	4/20
SCHEMBL924843	0.53	3/20
SCHEMBL48376	0.50	3/20
SCHEMBL189945	0.66	2/20
SCHEMBL48677	0.57	2/20
SCHEMBL48422	0.56	2/20
SCHEMBL188910	0.56	2/20
SCHEMBL188602	0.56	2/20
SCHEMBL189189	0.55	2/20
SCHEMBL189820	0.55	2/20
SCHEMBL48483	0.55	2/20
SCHEMBL48790	0.55	2/20
SCHEMBL48438	0.54	2/20
SCHEMBL189130	0.54	2/20
SCHEMBL48522	0.53	2/20
SCHEMBL48526	0.51	2/20
SCHEMBL49282	0.50	2/20
SCHEMBL270681	0.49	2/20
SCHEMBL48786	0.46	2/20

Clinical trials — most relevant to PIK3C2G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.	PHASE2	UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer	PHASE2	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	PHASE1	COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Exploring the Link Between Cancer Genetics and PPSP	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIK3C2G binder may also engage these)

Protein	Name	Similarity
O70167	—	0.998	O70167 →
O70173	—	0.996	O70173 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.989	landscape →
Q96C45	—	0.989	Q96C45 →
GSAP	Gamma-secretase-activating protein	0.988	landscape →
PIK3C2A	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	0.988	landscape →
Q14D04	—	0.987	Q14D04 →
Q5RAY1	—	0.987	Q5RAY1 →
Q5TGP6	—	0.987	Q5TGP6 →
Q6GPJ8	—	0.986	Q6GPJ8 →
PTPN13	Tyrosine-protein phosphatase non-receptor type 13	0.986	landscape →
Q86YR7	—	0.986	Q86YR7 →
Q80VH0	—	0.986	Q80VH0 →
Q3UPC7	—	0.986	Q3UPC7 →
Q5PQS3	—	0.986	Q5PQS3 →
Q9FY74	—	0.986	Q9FY74 →
Q9D2K4	—	0.986	Q9D2K4 →
Q96NH3	—	0.986	Q96NH3 →
Q6P2C0	—	0.986	Q6P2C0 →
Q9H579	—	0.986	Q9H579 →
Q8NG08	—	0.986	Q8NG08 →
Q9D565	—	0.986	Q9D565 →
Q8NHQ1	—	0.986	Q8NHQ1 →
Q008S8	—	0.986	Q008S8 →
Q3UHQ6	—	0.986	Q3UHQ6 →
Q8BMD7	—	0.986	Q8BMD7 →
Q61194	—	0.986	Q61194 →
Q6P1Y8	—	0.985	Q6P1Y8 →
Q5TB30	—	0.985	Q5TB30 →
Q9ESK9	—	0.985	Q9ESK9 →